Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung cancer: An analytical database

Murray, S; Dahabreh, IJ; Linardou, H; Manoloukos, M; Bafaloukos, D; Kosmidis, P

dc.contributor.author	Murray, S	en
dc.contributor.author	Dahabreh, IJ	en
dc.contributor.author	Linardou, H	en
dc.contributor.author	Manoloukos, M	en
dc.contributor.author	Bafaloukos, D	en
dc.contributor.author	Kosmidis, P	en
dc.date.accessioned	2014-03-01T01:57:36Z
dc.date.available	2014-03-01T01:57:36Z
dc.date.issued	2008	en
dc.identifier.issn	1556-0864	en
dc.identifier.uri	https://dspace.lib.ntua.gr/xmlui/handle/123456789/28449
dc.subject	gefitinib	en
dc.subject	erlotinib	en
dc.subject	non-small cell lung cancer	en
dc.subject	smoking	en
dc.subject	adenocarcinoma	en
dc.subject.classification	Oncology	en
dc.subject.classification	Respiratory System	en
dc.subject.other	PHASE-III TRIAL	en
dc.subject.other	GEFITINIB THERAPY	en
dc.subject.other	EGFR MUTATIONS	en
dc.subject.other	GENE-MUTATIONS	en
dc.subject.other	ERLOTINIB	en
dc.subject.other	COMBINATION	en
dc.subject.other	CHEMOTHERAPY	en
dc.subject.other	RESPONSIVENESS	en
dc.subject.other	GEMCITABINE	en
dc.subject.other	CARBOPLATIN	en
dc.title	Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung cancer: An analytical database	en
heal.type	journalArticle	en
heal.language	English	en
heal.publicationDate	2008	en
heal.abstract	Background: After the discovery of somatic mutations in the tyrosine kinase domain (exons 18-24) of the epidermal growth factor receptor (EGFR) correlating with responses of non-srnall cell lung cancer (NSCLC) to the tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib, there has been increasing interest in utilizing this molecular marker for treatment selection. We aimed to analytically catalogue the Mutational spectrum of somatic Mutations in EGFR and format a database allowing correlation of specific mutations with clinico-pathologic factors and response to TKIs. Methods: A computerized search of MEDLINE (January I 2004 to,June 30, 2007) was performed to identify articles reporting on NSCLC patients harboring somatic mutations in EGFR. Demographic, clinico-pathologic, Mutational, and response data were extracted and tabulated. Results: A total of 202 eligible articles were identified. We report data on 12,244 patients with 3381 somatic EGFR mutations. The majority Of mutations have been reported on only one occasion (158 of 254, 62.2%), and only nine Mutations occur at a rate of L858R and delE746-A750 account for 32.84% and 24.28% of all mutations, respectively; with 50% of mutations being exon 19 deletions or "deletional-insertions." There is a clear association between the presence of Mutations and response to TKI. Conclusions: We have generated a free access, nonprofit online analytical database of somatic EGFR mutations in NSCLC. Cumulative information will be made available through a routine update of both database tables and associated graphical representations. Direct updates and Submissions through the online site (www.somaticmutations-EGFR.org) are encouraged, as are comments and suggestions.	en
heal.publisher	LIPPINCOTT WILLIAMS & WILKINS	en
heal.journalName	JOURNAL OF THORACIC ONCOLOGY	en
dc.identifier.isi	ISI:000258447300005	en
dc.identifier.volume	3	en
dc.identifier.issue	8	en
dc.identifier.spage	832	en
dc.identifier.epage	839	en